// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

J Panes - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

ABT-494

Reducing the overprescribing of oral corticosteroids in IBD using a steroid assessment tool

G Scott - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Despite surveillance and increased use of biologics and immunosuppressives colorectal cancer detection in IBD patients remains unchanged over the past ten years

U N Shivaji - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Incidence and management of immunotherapy-induced colitis in a tertiary melanoma and IBD centre: Clinical practice data

V Cheung - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Ipilimumab

Long-term outcomes of paediatric patients admitted for Acute Severe Colitis - a multicentre study from the paediatric IBD porto group of ESPGHAN

A Krauthammer - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

3D reconstructions in complex fistulising perianal Crohn’s disease to aid decision-making

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Methadone hydrochloride

Refinement and confirmation of psychometric properties of the Inflammatory Bowel Disease Distress Scale (IBD-DS): A new tool to measure disease-specific distress

L Dibley - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study

J Segal - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Exploring mucosal function as a clinical endpoint in ulcerative colitis

S Kjaergaard - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Fertility and reproduction in a tertiary IBD centre: the Oxford experience

L H Lee - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

N/A

N/A

Asking about bowel control problems in IBD: Results of face-to-face screening vs. self-reporting

C Norton - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC)

A Walsh - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Molecular screening for Lynch syndrome in IBD colorectal cancer

C Anele - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A prospective multicentre “real-life” international validation study of the PICaSSO endoscopic scoring system against histologic scoring system to define mucosal healing in ulcerative colitis

M Iacucci - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Development of the Paediatric Inflammatory Crohn's MRE Index (PICMI)- results from the ImageKids Study

D Turner - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A randomised crossover trial of conventional vs. virtual chromoendoscopy for colitis surveillance: dysplasia detection, feasibility, and patient acceptability (CONVINCE)

S Gulati - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Analysis of various central endoscopy reading methodologies in the BERGAMOT exploratory induction cohort evaluating etrolizumab in Crohn’s Disease

W Reinisch - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Etrolizumab

Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ustekinumab

Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies

J -F Colombel - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ustekinumab

Developing a colorectal cancer risk prediction tool for patients with ulcerative colitis and low-grade dysplasia

M Kabir - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved